#China #Hong Kong #weight loss #Ascletis #ECO

Ascletis Showcases Innovative Weight Loss Solutions at ECO 2026 Conference

Ascletis Pharma Inc., a company committed to advancing treatments for metabolic diseases, is set to make significant presentations at the upcoming 33rd European Congress on Obesity (ECO 2026) from May 12-15, 2026, in Istanbul, Türkiye. During this prestigious event, Ascletis will present several poster sessions focused on its latest developments in obesity management therapies, highlighting impressive results from clinical and preclinical studies.

Exciting Presentations at ECO 2026

Among the key presentations, Ascletis will showcase data on ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist designed for muscle-preserving weight loss. In a significant finding, the Phase I data demonstrated that ASC47, when used in combination with semaglutide, achieved up to 111.8% greater relative weight loss in participants with obesity compared to those treated with semaglutide alone. This evidence positions ASC47 as a promising candidate in the fight against obesity.

Further, Ascletis will dive into the preclinical data of ASC36, a next-generation amylin receptor agonist peptide. This innovative therapeutic option has shown an impressive average observed half-life of 32 days in non-human primate models, offering a six-fold extension compared to current therapies like petrelintide. Notably, ASC36 led to 91% more relative weight loss than petrelintide in diet-induced obese rat models. These results highlight the potential of ASC36 as a powerful weapon in weight management.

Key Presentation Details

- Title: ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight Loss in Participants with Obesity Compared to Semaglutide Monotherapy

- Session Track: 4 Obesity Management and Intervention (PO4.264)
- Date/Time: Thursday, 14 May, 2026, 1800–1915 TRT

- Title: ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated a 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model

- Session Track: 4 Obesity Management and Intervention (PO4.270)
- Date/Time: Thursday, 14 May, 2026, 1800–1915 TRT

- Title: ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated a 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model

- Session Track: 4 Obesity Management and Intervention (PO4.263)
- Date/Time: Thursday, 14 May, 2026, 1800–1915 TRT

For those interested in obesity management and innovative therapeutic options, ASC’s presentations at ECO 2026 are poised to be a significant event. More information about the congress is available at ECO 2026.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a biotechnology firm that emphasizes the development of cutting-edge treatments for various metabolic diseases. With a focus on creating best-in-class and first-in-class therapeutics, Ascletis employs its proprietary technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platforms to manufacture advanced treatment options.

Additionally, the company has developed several drug candidates, including ASC30, a GLP-1 receptor agonist aiming to facilitate weight management, and ASC35, which acts as a GLP-1R/GIPR dual agonist peptide. With its robust pipeline, Ascletis remains dedicated to battling the global obesity epidemic and enhancing the quality of life for individuals affected by metabolic disorders.

For further details, please visit Ascletis.

For media inquiries, please reach out to: